Nicholas J Loman
Overview
Explore the profile of Nicholas J Loman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
13035
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
McCrone J, Hill V, Bajaj S, Pena R, Lambert B, Inward R, et al.
Res Sq
. 2022 Jan;
PMID: 34981043
The Delta variant of concern of SARS-CoV-2 has spread globally causing large outbreaks and resurgences of COVID-19 cases. The emergence of Delta in the UK occurred on the background of...
12.
Jackson B, Boni M, Bull M, Colleran A, Colquhoun R, Darby A, et al.
Cell
. 2021 Sep;
184(20):5179-5188.e8.
PMID: 34499854
We present evidence for multiple independent origins of recombinant SARS-CoV-2 viruses sampled from late 2020 and early 2021 in the United Kingdom. Their genomes carry single-nucleotide polymorphisms and deletions that...
13.
Kraemer M, Hill V, Ruis C, Dellicour S, Bajaj S, McCrone J, et al.
Science
. 2021 Jul;
373(6557):889-895.
PMID: 34301854
Understanding the causes and consequences of the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is crucial to pandemic control yet difficult to achieve because they...
14.
Kaur P, Potluri V, Ahuja V, Naveenkumar C, Krishnamurthy R, Gangadharaiah S, et al.
Tuberculosis (Edinb)
. 2021 Jul;
129:102104.
PMID: 34214859
FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited...
15.
Nicholls S, Poplawski R, Bull M, Underwood A, Chapman M, Abu-Dahab K, et al.
Genome Biol
. 2021 Jul;
22(1):196.
PMID: 34210356
In response to the ongoing SARS-CoV-2 pandemic in the UK, the COVID-19 Genomics UK (COG-UK) consortium was formed to rapidly sequence SARS-CoV-2 genomes as part of a national-scale genomic surveillance...
16.
Volz E, Mishra S, Chand M, Barrett J, Johnson R, Geidelberg L, et al.
Nature
. 2021 Mar;
593(7858):266-269.
PMID: 33767447
The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England, was first identified in the UK in late summer to early autumn 2020. Whole-genome SARS-CoV-2 sequence...
17.
Moore M, Lamont I, Williams D, Paterson S, Kukavica-Ibrulj I, Tucker N, et al.
Microb Genom
. 2021 Mar;
7(3).
PMID: 33720817
The Liverpool epidemic strain (LES) is an important transmissible clonal lineage of that chronically infects the lungs of people with cystic fibrosis (CF). Previous studies have focused on the genomics...
18.
Low L, Fuentes-Utrilla P, Hodson J, ONeil J, Rossiter A, Begum G, et al.
PeerJ
. 2021 Feb;
9:e10778.
PMID: 33628638
Background: Microbial keratitis is a leading cause of preventable blindness worldwide. Conventional sampling and culture techniques are time-consuming, with over 40% of cases being culture-negative. Nanopore sequencing technology is portable...
19.
du Plessis L, McCrone J, Zarebski A, Hill V, Ruis C, Gutierrez B, et al.
Science
. 2021 Jan;
371(6530):708-712.
PMID: 33419936
The United Kingdom's COVID-19 epidemic during early 2020 was one of world's largest and was unusually well represented by virus genomic sampling. We determined the fine-scale genetic lineage structure of...
20.
Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A, et al.
Cell
. 2020 Dec;
184(1):64-75.e11.
PMID: 33275900
Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate...